查看文章

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

• It has been suggested that the human paraoxonase‐1 (PON1) genotype is an important determinant of the therapeutic response given to statin treatment.

• It is also known that the PON1 activity status is a better predictor of coronary heart disease risk than any of the known PON1 genotypes.

• Our goal was to answer this previously uninvestigated, still clinically relevant question: does the PON1 phenotype have an impact on the paraoxonase‐activating and lipid‐lowering effect of different types of statins.

WHAT THIS STUDY ADDS

• All the statins (atorvastatin, simvastatin and fluvastatin) included in this study were able to increase serum paraoxonase activity and decrease triglyceride levels effectively; however, this response seemed to be more significant in patients with AB+BB PON1 phenotype than in those bearing AA PON1 phenotype.

• Furthermore …